151 related articles for article (PubMed ID: 24900329)
21. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
Xue CB; Chen L; Cao G; Zhang K; Wang A; Meloni D; Glenn J; Anand R; Xia M; Kong L; Huang T; Feng H; Zheng C; Li M; Galya L; Zhou J; Shin N; Baribaud F; Solomon K; Scherle P; Zhao B; Diamond S; Emm T; Keller D; Contel N; Yeleswaram S; Vaddi K; Hollis G; Newton R; Friedman S; Metcalf B
ACS Med Chem Lett; 2010 Dec; 1(9):483-7. PubMed ID: 24900235
[TBL] [Abstract][Full Text] [Related]
22. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation.
Padi SSV; Shi XQ; Zhao YQ; Ruff MR; Baichoo N; Pert CB; Zhang J
Pain; 2012 Jan; 153(1):95-106. PubMed ID: 22033364
[TBL] [Abstract][Full Text] [Related]
23. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.
Liang M; Mallari C; Rosser M; Ng HP; May K; Monahan S; Bauman JG; Islam I; Ghannam A; Buckman B; Shaw K; Wei GP; Xu W; Zhao Z; Ho E; Shen J; Oanh H; Subramanyam B; Vergona R; Taub D; Dunning L; Harvey S; Snider RM; Hesselgesser J; Morrissey MM; Perez HD
J Biol Chem; 2000 Jun; 275(25):19000-8. PubMed ID: 10748002
[TBL] [Abstract][Full Text] [Related]
25. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.
Gladue RP; Tylaska LA; Brissette WH; Lira PD; Kath JC; Poss CS; Brown MF; Paradis TJ; Conklyn MJ; Ogborne KT; McGlynn MA; Lillie BM; DiRico AP; Mairs EN; McElroy EB; Martin WH; Stock IA; Shepard RM; Showell HJ; Neote K
J Biol Chem; 2003 Oct; 278(42):40473-80. PubMed ID: 12909630
[TBL] [Abstract][Full Text] [Related]
26. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.
Fretz H; Valdenaire A; Pothier J; Hilpert K; Gnerre C; Peter O; Leroy X; Riederer MA
J Med Chem; 2013 Jun; 56(12):4899-911. PubMed ID: 23721423
[TBL] [Abstract][Full Text] [Related]
27. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.
Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ
Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
[TBL] [Abstract][Full Text] [Related]
29. Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
Zheng C; Cao G; Xia M; Feng H; Glenn J; Anand R; Zhang K; Huang T; Wang A; Kong L; Li M; Galya L; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Baribaud F; Shin N; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B; Xue CB
Bioorg Med Chem Lett; 2011 Mar; 21(5):1442-6. PubMed ID: 21295478
[TBL] [Abstract][Full Text] [Related]
30. Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2.
Jarnagin K; Grunberger D; Mulkins M; Wong B; Hemmerich S; Paavola C; Bloom A; Bhakta S; Diehl F; Freedman R; McCarley D; Polsky I; Ping-Tsou A; Kosaka A; Handel TM
Biochemistry; 1999 Dec; 38(49):16167-77. PubMed ID: 10587439
[TBL] [Abstract][Full Text] [Related]
31. Structure prediction and molecular dynamics simulations of a G-protein coupled receptor: human CCR2 receptor.
Singh R; Sobhia ME
J Biomol Struct Dyn; 2013; 31(7):694-715. PubMed ID: 22909007
[TBL] [Abstract][Full Text] [Related]
32. Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.
Yang MG; Xiao Z; Cherney RJ; Tebben AJ; Batt DG; Brown GD; Chen J; Cvijic ME; Dabros M; Duncia JV; Galella M; Gardner DS; Khandelwal P; Ko SS; Malley MF; Mo R; Pang J; Rose AV; Santella JB; Shi H; Srivastava A; Traeger SC; Wang B; Xu S; Zhao R; Barrish JC; Mandlekar S; Zhao Q; Carter PH
ACS Med Chem Lett; 2019 Mar; 10(3):300-305. PubMed ID: 30891130
[TBL] [Abstract][Full Text] [Related]
33. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
Pettipher R; Vinall SL; Xue L; Speight G; Townsend ER; Gazi L; Whelan CJ; Armer RE; Payton MA; Hunter MG
J Pharmacol Exp Ther; 2012 Feb; 340(2):473-82. PubMed ID: 22106101
[TBL] [Abstract][Full Text] [Related]
35. A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
Subasinghe NL; Lanter J; Markotan T; Opas E; McKenney S; Crysler C; Hou C; O'Neill J; Johnson D; Sui Z
Bioorg Med Chem Lett; 2013 Feb; 23(4):1063-9. PubMed ID: 23294701
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.
Xia M; Hou C; Pollack S; Brackley J; DeMong D; Pan M; Singer M; Matheis M; Olini G; Cavender D; Wachter M
Bioorg Med Chem Lett; 2007 Nov; 17(21):5964-8. PubMed ID: 17869105
[TBL] [Abstract][Full Text] [Related]
37. The regulation and importance of monocyte chemoattractant protein-1.
Bianconi V; Sahebkar A; Atkin SL; Pirro M
Curr Opin Hematol; 2018 Jan; 25(1):44-51. PubMed ID: 28914666
[TBL] [Abstract][Full Text] [Related]
38. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration.
Connolly S; Skrinjar M; Rosendahl A
Biochem Pharmacol; 2012 Mar; 83(6):778-87. PubMed ID: 22209712
[TBL] [Abstract][Full Text] [Related]
39. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
[TBL] [Abstract][Full Text] [Related]
40. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
